

=====

Sequence Listing was accepted.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).

Reviewer: Durreshwar Anjum

Timestamp: Fri Sep 07 13:09:36 EDT 2007

=====

Application No: 10554372

Version No: 1.0

Input Set:

Output Set:

Started: 2007-08-24 14:29:39.054

Finished: 2007-08-24 14:29:43.444

Elapsed: 0 hr(s) 0 min(s) 4 sec(s) 390 ms

Total Warnings: 12

Total Errors: 23

No. of SeqIDs Defined: 13

Actual SeqID Count: 13

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
E 257	Invalid sequence data feature in <221> in SEQ ID (1)
E 257	Invalid sequence data feature in <221> in SEQ ID (1)
E 257	Invalid sequence data feature in <221> in SEQ ID (1)
E 257	Invalid sequence data feature in <221> in SEQ ID (1)
E 257	Invalid sequence data feature in <221> in SEQ ID (1)
E 257	Invalid sequence data feature in <221> in SEQ ID (1)
E 257	Invalid sequence data feature in <221> in SEQ ID (1)
E 257	Invalid sequence data feature in <221> in SEQ ID (1)
E 257	Invalid sequence data feature in <221> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
E 257	Invalid sequence data feature in <221> in SEQ ID (2)
E 257	Invalid sequence data feature in <221> in SEQ ID (2)
E 257	Invalid sequence data feature in <221> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
E 257	Invalid sequence data feature in <221> in SEQ ID (3)
E 257	Invalid sequence data feature in <221> in SEQ ID (3)
E 257	Invalid sequence data feature in <221> in SEQ ID (3)
E 257	Invalid sequence data feature in <221> in SEQ ID (3)
E 257	Invalid sequence data feature in <221> in SEQ ID (3)

Input Set:

Output Set:

Started: 2007-08-24 14:29:39.054
Finished: 2007-08-24 14:29:43.444
Elapsed: 0 hr(s) 0 min(s) 4 sec(s) 390 ms
Total Warnings: 12
Total Errors: 23
No. of SeqIDs Defined: 13
Actual SeqID Count: 13

Error code	Error Description
E 257	Invalid sequence data feature in <221> in SEQ ID (3)
E 257	Invalid sequence data feature in <221> in SEQ ID (3)
E 257	Invalid sequence data feature in <221> in SEQ ID (3) This error has occurred more than 20 times, will not be displayed
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)
W 213	Artificial or Unknown found in <213> in SEQ ID (13)

SEQUENCE LISTING

<110> BARBERO, LUCA
 ESPOSITO, PIERANDREA
 TRAVERSA, SILVIO

<120> BETA-AMYLOID INHIBITORS AND USE THEREOF

<130> 279681US0PCT

<140> 10554372

<141> 2007-08-24

<150> PCT/EP2004/004807

<151> 2004-04-29

<150> EP 03101202.4

<151> 2003-04-30

<160> 13

<170> PatentIn Ver. 3.3

<210> 1

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 peptide

<220>

<221> MOD_RES

<222> (1)

<223> May or may not be present

<220>

<221> MOD_RES

<222> (2)

<223> Ile, Leu or not present

<220>

<221> MOD_RES

<222> (3)

<223> Pro, Trp or not present

<220>

<221> MOD_RES

<222> (4) .. (5)

<223> May or may not be present

<220>

<221> MOD_RES

<222> (10)

<223> Ile or Leu

<220>
<221> MOD_RES
<222> (14)
<223> May or may not be present

<220>
<221> MOD_RES
<222> (15)
<223> Ile, Leu or not present

<220>
<221> MOD_RES
<222> (16)..(18)
<223> May or may not be present

<220>
<221> MOD_RES
<222> (19)..(26)
<223> Variable amino acid and this region may encompass
1 to 8 residues

<220>
<223> N-term may or may not be acetylated

<220>
<223> C-term amidated

<220>
<223> see specification as filed for detailed description of
substitutions and preferred embodiments

<400> 1
Lys Xaa Xaa Phe Gln Arg Gln Ile Lys Xaa Pro Phe Gln Lys Xaa Pro
1 5 10 15

Phe Gln Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25

<210> 2
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (2)..(3)
<223> Arg or Lys

<220>
<221> MOD_RES
<222> (5)

<223> Arg or Lys

<220>

<221> MOD_RES

<222> (7)..(8)

<223> Arg or Lys

<220>

<223> C-term amidated

<400> 2

Asn Xaa Xaa Met Xaa Trp Xaa Xaa

1 5

<210> 3

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<221> MOD_RES

<222> (1)

<223> May or may not be present

<220>

<221> MOD_RES

<222> (2)

<223> Ile, Leu or not present

<220>

<221> MOD_RES

<222> (3)

<223> Pro, Trp or not present

<220>

<221> MOD_RES

<222> (4)..(5)

<223> May or may not be present

<220>

<221> MOD_RES

<222> (10)

<223> Ile or Leu

<220>

<221> MOD_RES

<222> (11)

<223> Pro or Trp

<220>

<221> MOD_RES

<222> (14)

<223> May or may not be present

<220>

<221> MOD_RES

<222> (15)

<223> Ile, Leu or not present

<220>

<221> MOD_RES

<222> (16)

<223> Pro, Trp or not present

<220>

<221> MOD_RES

<222> (17)..(18)

<223> May or may not be present

<220>

<221> MOD_RES

<222> (19)..(26)

<223> Variable amino acid and this region may encompass
1 to 8 residues

<220>

<223> N-term may or may not be acetylated

<220>

<223> C-term amidated

<220>

<223> see specification as filed for detailed description of
substitutions and preferred embodiments

<400> 3

Lys Xaa Xaa Phe Gln Arg Gln Ile Lys Xaa Xaa Phe Gln Lys Xaa Xaa
1 5 10 15

Phe Gln Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25

<210> 4

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<223> C-term amidated

<400> 4

Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys
1 5 10 15

<210> 5
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<223> N-term acetylated

<220>
<223> C-term amidated

<400> 5
Leu Pro Phe Phe Asp
1 5

<210> 6
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<223> C-term amidated

<400> 6
Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys
1 5 10 15

Leu Pro Phe Phe Asp
20

<210> 7
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<223> N-term acetylated

<220>
<223> C-term amidated

<400> 7

Arg Gln Ile Lys Ile Pro Phe Gln Asn Arg Arg Met Lys Trp Lys Lys
1 5 10 15

<210> 8

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<223> N-term acetylated

<220>

<223> C-term amidated

<400> 8

Arg Gln Ile Lys Ile Pro Phe Gln Lys Ile Pro Phe Gln Asn Arg Arg
1 5 10 15

Met Lys Trp Lys Lys
20

<210> 9

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<223> N-term acetylated

<220>

<223> C-term amidated

<400> 9

Lys Ile Trp Phe Gln Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg
1 5 10 15

Met Lys Trp Lys Lys
20

<210> 10

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

peptide

<220>

<223> C-term amidated

<400> 10

Asn Arg Arg Met Lys Trp Lys Lys

1 5

<210> 11

<211> 42

<212> PRT

<213> Homo sapiens

<400> 11

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys

1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile

20 25 30

Gly Leu Met Val Gly Gly Val Val Ile Ala

35 40

<210> 12

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 12

Lys Lys Lys Lys

1

<210> 13

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 13

Glu Glu Glu Glu

1